{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:50:28Z","timestamp":1768920628436,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002858","name":"Postdoctoral Science Foundation of China","doi-asserted-by":"crossref","award":["2015M580270"],"award-info":[{"award-number":["2015M580270"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Postdoctoral Science Foundation of Heilongjiang Province","award":["LRB156483"],"award-info":[{"award-number":["LRB156483"]}]},{"name":"Young and middle-aged Science Foundation of Harbin Medical University","award":["KYCX2018-15"],"award-info":[{"award-number":["KYCX2018-15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12288-022-01610-5","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:10:58Z","timestamp":1670515858000},"page":"383-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety Analysis of VRD-PDCE in Treatment-Native Patients with Multiple Extramedullary Plasmacytomas or Plasma Cell Leukemia"],"prefix":"10.1007","volume":"39","author":[{"given":"Weiwei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"1610_CR1","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince M, Harousseau J, Dmoszynska A, Miguel JS, Hellmann A, Facon T, Facon R, Facon A, Masliak Z, Olesnyckyj M, Yu ZN, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1610_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray MT, Thun MJ (2008) Cancer statistics. Ca-Cancer J Clin 58:71\u201396","journal-title":"Ca-Cancer J Clin"},{"key":"1610_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Merlini MV, Kumar S, Hillengass J, Hillengass E, Richardson P (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"1610_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/OTT.S35348","volume":"5","author":"TQ Wu","year":"2012","unstructured":"Wu TQ, Chen HF, Hou J, Li ZY, Tang JQ, Fu WJ, Yuan ZG, Shen HS (2012) Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Onco Targets Ther 5:329\u2013334","journal-title":"Onco Targets Ther"},{"key":"1610_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00277-005-0054-4","volume":"85","author":"VH Jim\u00e9nez-Zepeda","year":"2006","unstructured":"Jim\u00e9nez-Zepeda VH, Dom\u00ednguez VJ (2006) Plasma cell leukemia: a rare condition. Ann Hematol 85:263\u2013267","journal-title":"Ann Hematol"},{"key":"1610_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"1610_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2141.2010.08157.x","volume":"150","author":"T Sher","year":"2010","unstructured":"Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A (2010) Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol 150:418\u2013427","journal-title":"Br J Haematol"},{"key":"1610_CR8","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1002\/cncr.24700","volume":"115","author":"G Ramsingh","year":"2009","unstructured":"Ramsingh G, Mehan P, Luo JQ, Vij R, Morgensztern D, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K (2009) Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer 115:5734\u20135739","journal-title":"Cancer"},{"key":"1610_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","volume":"22","author":"RE Tiedemann","year":"2008","unstructured":"Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K (2008) Genetic aberrations and survival in plasma cell leukemia. Leukemia 22:1044\u20131052","journal-title":"Leukemia"},{"key":"1610_CR10","doi-asserted-by":"crossref","unstructured":"Garc\u0131 A-Sanz R, Orfa OA, Gonza Lez M, Tabernero MD, San Miguel JF (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93:1032\u20131037.","DOI":"10.1182\/blood.V93.3.1032.403a15_1032_1037"},{"key":"1610_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie B, Anaissie E, Rhee FV, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138:176\u2013185","journal-title":"Br J Haematol"},{"key":"1610_CR12","doi-asserted-by":"crossref","unstructured":"Rhee FV, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, John D.Jr S, Hoering\u00a0A, Crowley J, Barlogie B (2010)Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of vtd maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 116:1220\u20131227.","DOI":"10.1182\/blood-2010-01-264333"},{"key":"1610_CR13","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","volume":"24","author":"F Davies","year":"2010","unstructured":"Davies F, Baz R (2010) Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 24:S13\u2013S19","journal-title":"Blood Rev"},{"key":"1610_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.critrevonc.2011.04.005","volume":"82","author":"P Musto","year":"2012","unstructured":"Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Raimondo FD, Baldini L, Tosi P, Bringhen S, Offidani M (2012) Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 82:141\u2013149","journal-title":"Crit Rev Oncol Hematol"},{"key":"1610_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, Tardi PG, Mayer LD, Bally MB (2001) A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Saf 24:903\u2013920","journal-title":"Drug Saf"},{"key":"1610_CR16","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P, Blad\u00e9 J, Hajek R, Spencer A, Miguel JS, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan ZL, Rackoff W, Harousseau J (2007) Randomized phase iii study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892\u20133901","journal-title":"J Clin Oncol"},{"issue":"12","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers Z, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Anderson BGM, Miguel JSF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol 15(12):e538-548","journal-title":"Lancet Oncol"},{"key":"1610_CR18","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2012.e14","volume":"4","author":"R Safaee","year":"2012","unstructured":"Safaee R, Ahmadzadeh A, Sharifian R, Emami A, Yekaninejad MS, Jalili MH, Valizadeh A (2012) Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group. Hematol Rep 4:e14","journal-title":"Hematol Rep"},{"key":"1610_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4068\/cmj.2019.55.1.25","volume":"55","author":"SS Lee","year":"2019","unstructured":"Lee SS, Lee JJ (2019) Efficacy and safety of melphalan, cyclophosphamide and dexamethasone (mcd) as a salvage treatment for patients with relapsed\/refractory multiple myeloma. Chonnam Med J 55:25\u201330","journal-title":"Chonnam Med J"},{"key":"1610_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos M, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"1610_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"DLC Fernandez","year":"2013","unstructured":"Fernandez DLC, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, Hajek R, Miguel JFS, Sezer O, Sonneveld P (2013) Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group. Leukemia 27:780\u2013791","journal-title":"Leukemia"},{"key":"1610_CR22","unstructured":"Tumor clinical chemotherapy professional committee of China Anti Cancer Association, tumor support treatment professional committee of China Anti Cancer Association (2020) Expert diagnosis and treatment consensus of chemotherapy-related thrombocytopenia in China (2019). Chin J Medical Front 2(1):51\u201358."},{"key":"1610_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-011-0079-0","volume":"28","author":"A Oriol","year":"2011","unstructured":"Oriol A (2011) Multiple myeloma with extramedullary disease. Adv Ther 28:1\u20136","journal-title":"Adv Ther"},{"key":"1610_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21:325\u2013330","journal-title":"Ann Oncol"},{"key":"1610_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12185-009-0288-3","volume":"89","author":"VH Jimenez-Zepeda","year":"2009","unstructured":"Jimenez-Zepeda VH, Dominguez-Martinez VJ (2009) Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 89:259\u2013268","journal-title":"Int J Hematol"},{"key":"1610_CR26","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1177\/0300060516664820","volume":"44","author":"WJ Sun","year":"2016","unstructured":"Sun WJ, Zhang JJ, Na A, Shen M, Li X (2016) Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. J Int Med Res 44:1462\u20131473","journal-title":"J Int Med Res"},{"key":"1610_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000109470","volume":"118","author":"CH Cha","year":"2007","unstructured":"Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK (2007) Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 118:178\u2013182","journal-title":"Acta Haematol"},{"key":"1610_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-0609.2011.01629.x","volume":"87","author":"VH Jimenez-Zepeda","year":"2011","unstructured":"Jimenez-Zepeda VH, Neme-Yunes Y, Braggio E (2011) Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology? Eur J Haematol 87:20\u201327","journal-title":"Eur J Haematol"},{"key":"1610_CR29","doi-asserted-by":"crossref","unstructured":"Musto P, Pietrantuono G, Guariglia R, Villani O, Martorelli MC, Auria F D\u2019, Zonno A,Lerose R. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk. Res. 2008;32:1637\u20131638.","DOI":"10.1016\/j.leukres.2008.03.013"},{"key":"1610_CR30","doi-asserted-by":"publisher","first-page":"8785","DOI":"10.4076\/1752-1947-3-8785","volume":"6","author":"P Leake","year":"2009","unstructured":"Leake P, Coard KC, Plummer JM (2009) Extramedullary plasmacytoma of the pancreas as an uncommon cause of obstructive jaundice: a case report. J Med Case Rep 6:8785\u20138789","journal-title":"J Med Case Rep"},{"key":"1610_CR31","first-page":"187","volume":"10","author":"M Atiq","year":"2009","unstructured":"Atiq M, Ali SA, Dang S, Krishna SG, Anaisse E, Olden KW, Aduli F (2009) Pancreatic plasmacytoma presenting as variceal hemorrhage: life threatening complication of a rare entity. JOP 10:187\u2013188","journal-title":"JOP"},{"key":"1610_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, Palumbo A (2014) European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99:232\u2013242","journal-title":"Haematologica"},{"key":"1610_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Ludwig H, Mellqvist U-H, Chng W-J, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O\u2019Gorman P, Terpos E, Dimopoulos M, Moreau P, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016) Management of relapsed multiple myeloma: recommendations of the international myeloma working group. Leukemia 30:1005\u20131017","journal-title":"Leukemia"},{"key":"1610_CR34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ajh.23810","volume":"89","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV (2014) Multiple myeloma: 2014 update on diagnosis, risk-stratification and management. Am J Hematol 89:999\u20131009","journal-title":"Am J Hematol"},{"key":"1610_CR35","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1002\/cncr.29533","volume":"121","author":"PT Griffin","year":"2015","unstructured":"Griffin PT, Ho VQ, Fulp W, Nishihori T, Baz RC (2015) A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma. Cancer 121:3622\u20133630","journal-title":"Cancer"},{"key":"1610_CR36","doi-asserted-by":"crossref","unstructured":"Gozzetti A, Musto P, Defina M, Auria FD\u2019, Papini G, Steduto T,\u00a0D\u2019Arena G,\u00a0Bocchia M. Efficacy of bortezomib, lenalidomide and dexamethasone (vrd) in secondary plasma cell leukaemia. Br. J. Haematol. 2012;157:497\u2013498.","DOI":"10.1111\/j.1365-2141.2012.09029.x"},{"key":"1610_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-017-3420-8","volume":"80","author":"KM Skubitz","year":"2017","unstructured":"Skubitz KM, Blaes AH, Konety SH, Francis GS (2017) Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol 80:787\u2013798","journal-title":"Cancer Chemother Pharmacol"},{"key":"1610_CR38","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau J-L, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blad\u00e9 J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"1610_CR39","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860\u20131873","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-022-01610-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T06:42:31Z","timestamp":1686120151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-022-01610-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s12288-022-01610-5","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"19 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"No potential conflict of interest was reported by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}